Suven Life Sciences (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Suven Life Sciences Limited |
|||
|
Price: ₹134.72 | ||
| 52 Week Low: ₹74.50 52 Week High: ₹169.30 |
|||
| Market Capital: 2,174.19 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Suven Life Sciences Share Price Target For 2024
- 1.1.1: Suven Life Sciences Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Suven Life Sciences Share Price Target For 2025
- 1.2.1: Suven Life Sciences Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Suven Life Sciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Suven Life Sciences Brief Company Overview
- 4: Suven Life Sciences Financial Performance
- 4.0.1: Is Suven Life Sciences A Good Buy For Long Term?
To predict the Suven Life Sciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Suven Life Sciences Share Price Target For 2024
The line chart displays the monthly closing prices of Suven Life Sciences with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Suven Life Sciences shares in 2024, see the table below.
Suven Life Sciences Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 145.3 (+7.85%) | Price Action: 19 Dec 2024 High |
| 2024 Target 2 | 142.92 (+6.08%) | Price Action: 09 Dec 2024 Low |
| 2024 Target 1 | 140.64 (+4.39%) | Price Action: 03 Dec 2024 High |
| Current Price | 134.72 | Suven Life Sciences's share price as of 20 Dec 2024 |
| Stop Loss 1 | 131.94 (-2.07%) | Price Action: 08 Nov 2024 High |
| Stop Loss 2 | 130.0 (-3.51%) | Price Action: 04 Nov 2024 High |
| Stop Loss 3 | 128.63 (-4.53%) | Price Action: Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Suven Life Sciences is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹134.87 serves as the nearest technical reference point.
Historical Returns: 3-month: -4.24% | 6-month: +28.02% | 1-year: +66.84%
Suven Life Sciences Share Price Target For 2025
The line chart displays the monthly closing prices of Suven Life Sciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Suven Life Sciences shares in 2025, see the table below.
Suven Life Sciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 199.98 (+48.44%) | Price Action: Chart |
| 2025 Target 2 | 196.25 (+45.67%) | Fibonacci Extension Level 64.90% |
| 2025 Target 1 | 191.67 (+42.27%) | Fibonacci Extension Level 123.60% |
| Current Price | 134.72 | Suven Life Sciences's share price as of 20 Dec 2024 |
| Stop Loss 1 | 120.66 (-10.44%) | Price Action: Aug 2024 Low |
| Stop Loss 2 | 118.49 (-12.05%) | Price Action: 14 Nov 2024 Low |
| Stop Loss 3 | 117.0 (-13.16%) | Price Action: 18 Nov 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Suven Life Sciences is currently trading at 63.5% of its 52-week range (₹74.5 - ₹169.3).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +66.84% | 3-year: +64.13% | 5-year: +844.74%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Suven Life Sciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹134.72 | ||
| 2024 | ₹160.03 | +18.79% | ₹162.43 |
| 2025 | ₹136.57 | -14.66% | ₹321.22 |
| 2026 | ₹438.51 | +221.09% | ₹445.09 |
| 2027 | ₹502.42 | +14.57% | ₹509.96 |
| 2028 | ₹467.84 | -6.88% | ₹613.24 |
| 2029 | ₹596.48 | +27.50% | ₹759.25 |
| 2030 | ₹377.58 | -36.70% | ₹905.26 |
| 2031 | ₹1,010.48 | +167.62% | ₹1,025.64 |
| 2032 | ₹1,022.15 | +1.15% | ₹1,037.48 |
| 2033 | ₹868.85 | -15.00% | ₹923.81 |
| 2034 | ₹1,032.93 | +18.88% | ₹1,048.42 |
| 2035 | ₹618.58 | -40.11% | ₹969.10 |
| 2036 | ₹1,582.45 | +155.82% | ₹1,606.19 |
| 2037 | ₹1,541.89 | -2.56% | ₹1,565.02 |
| 2038 | ₹1,269.85 | -17.64% | ₹1,288.90 |
| 2039 | ₹1,397.80 | +10.08% | ₹1,418.77 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Suven Life Sciences Brief Company Overview
Suven Life Sciences Limited: Leading the Way in Neurodegenerative Therapies Suven Life Sciences Limited, a renowned clinical-stage biopharmaceutical company, has dedicated itself to developing cutting-edge therapeutics for neurodegenerative disorders. Established...
in 1989 and headquartered in Hyderabad, India, Suven Life Sciences has a global presence, focusing on drug discovery and development of novel chemical entities (NCEs) for central nervous system therapies. Commitment to Innovation Suven Life Sciences is renowned for its extensive product range, including: Masupirdine: Treatment of Alzheimer's disease and neuropsychiatric symptoms Samelisant: Treatment of sleep and cognitive disorders Ropanicant: Treatment of depressive disorders Usmarapride: Treatment of cognitive disorders Other promising NCEs in various stages of development Suven Life Sciences' unwavering commitment to research and development has positioned them as a leader in the neurodegenerative field.Suven Life Sciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 2,174.19 Crore | Market valuation of Suven Life Sciences's shares. |
| Revenue (TTM) | 11.69 Crore | Total revenue generated by Suven Life Sciences over the past twelve months. |
| Net Income (TTM) | -1,050,763,008.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -1,333.07% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +100.00% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-10.60% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-8.66% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.26 | Company's total debt divided by total shareholder equity. |
| Total Debt | 70.97 Lakh | Sum of Suven Life Sciences's current & long-term financial obligations. |
| Total Cash | 242.11 Crore | Total amount of liquid funds available to Suven Life Sciences. |
| Beta | 1.51 | Beta is greater than 1 indicating that the Suven Life Sciences's price is more volatile than the market. |
Is Suven Life Sciences A Good Buy For Long Term?
Suven Life Sciences' recent financial performance has been mixed. Its net profit has declined in the last 12 months, and it has a relatively low profit margin. However, the company has strong cash reserves and its revenue has increased significantly over the past 3 years. Overall, the company's long-term prospects appear to be uncertain and it is difficult to recommend it as a buy or a sell at this time.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
